DOI : 10.1055/s-00000034

Klinische Pädiatrie

Issue 03 · Volume 224 · April 2012 DOI: 10.1055/s-002-23192


XXV. Jahrestagung der Kind-Philipp-Stiftung für Leukämieforschung
Wilsede, Lüneburger Heide, 6.–9. Juni 2012

Wissenschaftliche Leitung: Prof. Dr. M. Horstmann – Prof. Dr. R. Marschalek – Prof. Dr. M. Stanulla
Abstracts (HTML) List of Authors
A1
Elder, AK; Heidenreich, O; Vormoor, HJ: Lentiviralmarking as a tool to investigate the clonal complexity and evolution of ALL
A2
Streltsov, A; Emmrich, S; Engeland, F; Klusmann, JH: Molecular characterization of lincRNAs in Down syndrome associated leukemia
A3
Maroz, A; Hennig, C; Van Handel, B; Mikkola, H; Reinhardt, D; Klusmann, JH: Formation of atypical, hyperproliferating eosinophilic precursors by overexpression of GATA1s
A4
Ulmer, A; Tauer, JT; Suttorp, M: Influence of tyrosine kinase inhibitors (TKIs) on endocrinological parameters
A5
Torge, A; Zimmermann, M; Möricke, A; Köhler, R; Schrauder, A; Bartram, CR; Schrappe, M; Stanulla, M: A mathematical approach to data evaluation with focus on prediction of minimal residual disease in pediatric ALL
A6
Bonn, BR; Rohde, M; Zimmermann, M; Burkhardt, B: Differences in LOH6q and its prognostic impact on pediatric T-LBL and T-ALL
A7
Engeland, F; Emmrich, S; Kuipers, J; van den Heuvel-Eibrink, MM; Reinhardt, D; Klusmann, JH: Investigating the role of miR-139 and miR-582 in AML1-ETO associated leukemia
A8
Seyfried, F; Accordi, B; Queudeville, M; Eckhoff, SM; Milani, G; Galla, L; Giordan, M; Kraus, J; Basso, G; Kestler, H; te Kronnie, G; Debatin, KM; Meyer, LH: Reverse Phase Protein Array (RPPA) of High Risk ALL
A9
Wachter, F; Grunert, M; Jeremias, I; Ehrhardt, H: TRAIL targets cell cycle arrested tumor cells
A10
Hoffmann, J; Metzler, M; Stackelberg, A von; Eckert, C: MRD-quantification during treatment of ETV6-RUNX1 positive ALL relapses using the genomic breakpoint of the fusion gene
A11
Tauer, JT; Ulmer, A; Hofbauer, LC; Suttorp, M: Side effects of tyrosine kinase inhibitors (TKIs) on bone remodelling
A12
Stachorski, L; Thangapandi, VR; Reinhardt, D; Klusmann, JH: Characterization of oncogenes on chromosome 21 identified by shRNA-based viability screening
A13
Krumbholz, M; Goessel, H von; Karl, M; Berger, M; Metzler, M: Application of genomic breakpoints as molecular markers in pediatric leukemia and sarcoma
A14
Hasan, MN; Queudeville, M; Eckhoff, SM; Hermann, M; Miller, S; Trentin, L; Debatin, KM; Meyer, LH: Preclinical evaluation of a novel treatment strategy to treat high risk ALL
A15
Martinez, N; Ptasinska, A; Bonifer, C; Heidenreich, O: Depletion of RUNX1/ETO in t(8:21) AML cells leads to genome-wide changes in transcription factor binding
A16
Prall, S; Slack, J; Siekmann, I; Martinez, N; Heidenreich, O: Focal adhesion kinase (FAK) in t(8;21) rearranged acute myeloid leukaemia (AML)
A17
Anderl, S; Fortschegger, K; Dagmar, D; Strehl, S: The role of PAX5 fusion genes in the pathogenesis of B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
A18
Forster, V; Beyerle, A; Heidenreich, O; Allan, J: AML1/ETO Confers a Mutator Phenotype in AML
A19
Bastelberger, S; Grausenburger, R; Eckert, C; Stanulla, M; Panzer-Grümayer, R: Genetic aberrations involved in glucocorticoid-mediated response of ETV6/RUNX1-positive leukemia
A20
Bartram, T; Seidemann, K; Burkhardt, B; Wössmann, W; Zimmermann, M; Ellinghaus, E; Franke, A; Schreiber, S; Schrappe, M; Reiter, A; Stanulla, M: Role of three childhood acute lymphoblastic leukemia-associated SNPs in a pediatric non-Hodgkin lymphoma cohort